Tighter Standards Ahead for Generic Epilepsy Drugs

Studies are underway that may lead the FDA to stiffen its bioequivalence rules for generic anti-epileptic drugs (AEDs). Dr. Michael Privitera, a neurologist at the UC Gardner Neuroscience Institute’s Epilepsy Center, explains that after some hesitation the FDA has agreed that studies are necessary.

Read the story here>>

Media Outlet:
Med Page Today

This entry was posted in Articles. Bookmark the permalink. Both comments and trackbacks are currently closed.

Click Here to learn about our most recent updates, visitor restrictions, testing, safety precautions and more.